Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Cantor Fitzgerald

Generated: October 24, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,126,920

« Back to Dashboard

Summary for Patent: 6,126,920

Title: Method of treating a skin disease with a corticosteroid-containing pharmaceutical composition
Abstract:Methods of treating various skin diseases, and in particular, scalp psoriasis, utilizing a foamable pharmaceutical composition comprising a corticosteroid active substance, a quick-break foaming agent, a propellant and a buffering agent are disclosed. The quick-break foaming agent typically comprises an aliphatic alcohol, water, a fatty alcohol and a surface active agent.
Inventor(s): Jones; Julie Irene (Herpenden, GB), Baker; Anthony Richard (West Horsley, GB), Halls; Neil Graham (Glen Waverley, AU), Watmough; Peter (Grimsby, GB), Marriott; Peter (Grimsby, GB)
Assignee: Medeva Europe PLC (London, GB)
Application Number:08/913,144
Patent Claim Types:
see list of patent claims
Use; Composition;

No matches for this query

Foreign Priority and PCT Information for Patent: 6,126,920

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom9504265Mar 03, 1995
PCT Information
PCT FiledMarch 01, 1996PCT Application Number:PCT/GB96/00490
PCT Publication Date:September 12, 1996PCT Publication Number: WO96/27376

International Patent Family for Patent: 6,126,920

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada2214436► Subscribe
China1179720► Subscribe
China1082817► Subscribe
Czech Republic9702758► Subscribe
Czech Republic285913► Subscribe
Germany69630593► Subscribe
Denmark0813413► Subscribe
European Patent Office0813413► Subscribe
Hungary228890► Subscribe
Spain2210349► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

Google Plus